Lung Cancer Trials Ask AI to find trials
CompletedPhase 2NCT00066222
Official study title

Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Study summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cisplatin and etoposide together with radiation therapy works in treating patients with limited-stage small cell lung cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedCisplatin and Etoposide

Plus 1 other study approaches.

Who it may be forSmall cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 22, 2017 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?104 U.S. locations

Locations may change over time.

Who runs it?Radiation Therapy Oncology Group

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
Radiation Therapy Oncology Group
Interventions being studied
Drug: Cisplatin; Drug: Etoposide; Radiation: Radiation therapy
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Small cell lung cancer (SCLC)→
Treatment approach
Chemotherapy→Radiation therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • DISEASE CHARACTERISTICS:
  • Histologically or cytologically confirmed small cell carcinoma of the lung by fine needle aspiration biopsy or two positive sputa
  • Must have limited disease
  • Stage I, II, IIIA, or IIIB
  • Confined to 1 hemithorax, but excluding the following:
  • T4 tumor based on malignant pleural effusion
  • N3 disease based on contralateral hilar or contralateral supraclavicular involvement
  • No pericardial or pleural effusions on chest x-ray (regardless of cytology)
  • Measurable or evaluable disease
  • Tumor must be able to be encompassed by limited radiotherapy fields without significantly compromising pulmonary function
  • No prior complete tumor resection PATIENT CHARACTERISTICS: Age
  • 18 to 100 Performance status
  • Zubrod 0-1 Life expectancy
  • Not specified Hematopoietic
  • Absolute granulocyte count at least 1,500/mm\^3
  • Platelet count at least 150,000/mm\^3 Hepatic
  • Bilirubin no greater than 1.5 mg/dL Renal
  • Creatinine no greater than 1.5 mg/dL Cardiovascular
  • No myocardial infarction within the past 6 months
  • No symptomatic heart disease Pulmonary
  • No chronic obstructive pulmonary disease with Forced Expiratory Volume (FEV)-1 no greater than 0.8 liter
  • No uncontrolled bronchospasm in the unaffected lung Other
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Available for follow-up
  • No other malignancy within the past 2 years except curatively treated basal cell or squamous cell skin cancer or non-invasive in situ malignancies
  • No other concurrent serious medical illness
  • No uncontrolled psychiatric illness
  • No chronic alcohol or drug abuse PRIOR CONCURRENT THERAPY: Biologic therapy
  • Not specified Chemotherapy
  • No prior chemotherapy Endocrine therapy
  • Not specified Radiotherapy
  • No prior radiotherapy to the chest or other area containing a large amount of bone marrow (e.g., more than 75% of pelvic bone) Surgery
  • See Disease Characteristics

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Comprehensive Cancer Center at University of Alabama at BirminghamBirmingham, Alabama
  • Eden Medical CenterCastro Valley, California
  • Saint Rose HospitalHayward, California
  • Highland General Hospital at St. George's University School of MedicineOakland, California
  • Alta Bates Summit Medical Center - Summit CampusOakland, California
  • CCOP - Bay Area Tumor InstituteOakland, California
  • Valley Care Medical CenterPleasanton, California
  • Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical CenterPomona, California
  • J.C. Robinson, M.D. Regional Cancer CenterSan Pablo, California
  • Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical CenterSavannah, Georgia
  • St. Joseph Medical CenterBloomington, Illinois
  • Graham HospitalCanton, Illinois

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 22, 2017. Always confirm current availability with the study team.

View original record ↗